48,830
edits
Difference between revisions of "Malignant mesothelioma"
Jump to navigation
Jump to search
Malignant mesothelioma (view source)
Revision as of 18:36, 10 February 2022
, 18:36, 10 February 2022→Mesothelioma versus mesothelial hyperplasia
(→IHC: fix) |
|||
| Line 125: | Line 125: | ||
*GLUT1 +ve ~50% (vs. ~10%) | *GLUT1 +ve ~50% (vs. ~10%) | ||
*p53 +ve ~50% (vs. ~2%). | *p53 +ve ~50% (vs. ~2%). | ||
*BAP1 -ve.<ref name=pmid29085180>{{cite journal |authors=Pulford E, Huilgol K, Moffat D, Henderson DW, Klebe S |title=Malignant Mesothelioma, BAP1 Immunohistochemistry, and VEGFA: Does BAP1 Have Potential for Early Diagnosis and Assessment of Prognosis? |journal=Dis Markers |volume=2017 |issue= |pages=1310478 |date=2017 |pmid=29085180 |pmc=5612603 |doi=10.1155/2017/1310478 |url=}}</ref> | |||
Note: | Note: | ||